Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ARWR compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
ARWR
Arrowhead Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
ARWR
Arrowhead Pharmaceuticals, Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
ARWR: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ARWR, solid
LLY, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ARWR
4
AMGN
Amgen
customer
SRPT
Sarepta Therapeutics
customer
NVS
Novartis Pharma
customer
—
Takeda Pharmaceutical
unlisted
customer
Shared
0
No shared counterparties.
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
25 more · LLY chain
›
ARWR
Arrowhead Pharmaceuticals, Inc.
Change
60.49
0.00%
· post 59.64
Mkt cap
$8.5B
Revenue
$75M
Q3 FY26
Revenue
$829M
FY25
LLY
ELI Lilly & Co
Change
1,412.87
▲
+2.85%
· post 1,417.05
Closed
Oct 30 '26
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Closed
Oct 30 '26
ARWR
Arrowhead Pharmaceuticals, Inc.
vs
LLY
ELI Lilly & Co
60.49
0.00%
post 59.64
Price
1,412.87
▲
+2.85%
post 1,417.05
$8.5B
Mkt cap
$1.3T
Q3 FY26
$75M
Revenue
$24.4B
Q3 FY26
FY25
$829M
Revenue
$65.2B
FY25
Change
Change
ARWR
60.49
0.00%
vs
LLY
1,412.87
▲
+2.85%
Closed
Oct 30 '26